In the two studies of patients who had received many anti-HIV medicines in the past, 70% of those taking the approved dose of ritonavir-boosted Prezista (92 out of 131) and 21% of the patients taking the comparator protease inhibitors (26 out of 124) had at least a 90% reduction in viral load after 24 weeks.